August 19, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.

NEW YORK, Aug. 19, 2020 /PRNewswire/ —
WeissLaw LLP is investigating possible breaches of fiduciary…

NEW YORK, Aug. 19, 2020 /PRNewswire/ —

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Momenta Pharmaceuticals, Inc. (“MNTA” or the “Company”) (NASDAQ: MNTA) in connection with the proposed acquisition of the Company by Johnson & Johnson (“JNJ”) (NYSE: JNJ).  Under the terms of the acquisition agreement, which is structured as a tender offer, MNTA shareholders will receive $52.50 in cash for each share of MNTA common stock that they own.

If you own MNTA shares and wish to discuss this investigation or have any questions concerning this notice, your rights or interests, or the potential tender of your shares, visit our website:

Or please contact:

Joshua Rubin, Esq.

WeissLaw LLP

1500 Broadway, 16th Floor

New York, NY  10036

(212) 682-3025

(888) 593-4771

WeissLaw is investigating whether MNTA’s board acted to maximize shareholder value in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the proposed acquisition of the Company, and whether all information regarding the valuation of the deal will be fully and fairly disclosed to MNTA shareholders.  Notably, the per-share offer price is less than the $53.00 price target recommended by several analysts.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at


Cision View original content to download multimedia: